Inflammation implicated in exfoliation syndrome
Mar. 28, 2023—Computational genetics tools have implicated inflammatory pathways in exfoliation syndrome, the most common cause of secondary glaucoma, which can result in blindness.
Opening a window to glaucoma
Oct. 10, 2022—A metalloprotease enzyme plays an important role in retinal ganglion cell development, Vanderbilt researchers discovered; studying it and other family members may lead to the identification of novel targets for treating glaucoma.
Mitochondria and retinal degeneration
Aug. 15, 2022—Vanderbilt researchers have developed a new cellular model for exploring mitochondrial dysfunction in age-related macular degeneration, the leading cause of blindness in people over 65.
New clue to lung scarring
May. 20, 2021—Vanderbilt neonatology team pinpoints signaling pathways involved in the progressive lung fibrosis that occurs in rare genetic diseases.
Insights on diabetic retinopathy
Jan. 23, 2020—A drug that targets multiple pathogenic steps in diabetic retinopathy may be an ideal therapeutic strategy for the disease, Vanderbilt researchers report.
Potassium balance and glaucoma
Jul. 15, 2019—Vanderbilt Eye Institute researchers have discovered that an imbalance in the ionic environment of retinal ganglion cells may contribute to functional impairments in glaucoma.
The arrestin-GPCR connection
Apr. 11, 2019—Understanding details of how arrestins deactivate signaling by G-protein coupled receptors is key to the design of new therapeutics aimed at these cellular "inboxes" that are targeted by up to half of all pharmaceuticals.
Novel methods to treat glaucoma
Nov. 8, 2018—Increasing a certain signaling molecule prevents the degeneration of retinal cells that are lost in glaucoma, suggesting a new way to treat this disease.
Cellular stress defense
Oct. 12, 2018—The modular architecture of small heat-shock proteins contributes to the ability of these proteins to aid cells in responding to stress.
Aqueous humor, microRNAs and glaucoma
Apr. 10, 2018—New findings highlight microRNAs — molecules that regulate gene expression — that are differentially expressed in glaucoma and could be candidate biomarkers or targets for therapy.
A cataract-heart connection
Jan. 25, 2018—Studies of alpha-B crystallin in zebrafish could ultimately lead to improved treatment for cataracts and heart disease.
Cytokine linked to blindness
Jun. 30, 2017—A signaling molecule called interleukin-6 may be a therapeutic target to prevent vision loss or nerve degeneration in glaucoma, Vanderbilt researchers have discovered.